SAB Biotherapeutics Yönetim

Yönetim kriter kontrolleri 4/4

SAB Biotherapeutics CEO'su Samuel Reich, Jan2024 tarihinde atandı, in görev süresi bir yıldan az. in toplam yıllık tazminatı $ 768.40K olup, şirket hissesi ve opsiyonları dahil olmak üzere 45.5% maaş ve 54.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.24% ine doğrudan sahiptir ve bu hisseler $ 67.01K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.5 yıl ve 4.4 yıldır.

Anahtar bilgiler

Samuel Reich

İcra Kurulu Başkanı

US$768.4k

Toplam tazminat

CEO maaş yüzdesi	45.5%
CEO görev süresi	less than a year
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	2.5yrs
Yönetim Kurulu ortalama görev süresi	4.4yrs

Son yönetim güncellemeleri

Recent updates

SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely

Sep 22

Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified

Apr 17

Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week

Jan 20

Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues

Nov 19

Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Nov 18

SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial

Sep 28

What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates

Aug 12

SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03

Aug 10

Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term

Apr 06

SAB Biotherapeutics: Advancing A New Class Of Immunotherapies Leveraging Polyclonal Antibodies

Dec 02

CEO Tazminat Analizi

Samuel Reich'un ücretlendirmesi SAB Biotherapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$46m
Jun 30 2024	n/a	n/a	-US$40m
Mar 31 2024	n/a	n/a	-US$40m
Dec 31 2023	US$768k	US$350k	-US$42m
Sep 30 2023	n/a	n/a	-US$27m
Jun 30 2023	n/a	n/a	-US$29m
Mar 31 2023	n/a	n/a	-US$27m
Dec 31 2022	US$985k	US$350k	-US$19m
Sep 30 2022	n/a	n/a	-US$22m
Jun 30 2022	n/a	n/a	-US$19m
Mar 31 2022	n/a	n/a	-US$18m
Dec 31 2021	US$3m	US$53k	-US$17m

Tazminat ve Piyasa: Samuel 'ın toplam tazminatı ($USD 768.40K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 652.28K ).

Tazminat ve Kazançlar: Samuel 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Samuel Reich (49 yo)

less than a year

Görev süresi

US$768,396

Tazminat

Mr. Samuel J. Reich is CEO of SAB Biotherapeutics, Inc. from January 30, 2024 and serves as its Executive Chairman since October 22, 2021 and serves as its Director since November 2020. Samuel J. Reich has...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Samuel Reich	CEO & Executive Chairman	less than a year	US$768.40k	0.24% $ 67.0k
Eddie Sullivan	Co-Founder	10.8yrs	US$807.76k	5.67% $ 1.6m
Christine Hamilton	Co-Founder & Independent Director	no data	US$25.00k	5.63% $ 1.6m
Christoph Bausch	Executive VP & COO	2.5yrs	US$549.32k	1.08% $ 305.2k
Alexandra Kropotova	Executive VP & Chief Medical Officer	2.4yrs	US$921.58k	0% $ 0
Edward Hamilton	Co-Founder & Board Observer	no data	Veri yok	3.15% $ 890.2k
Carlos Carillo	Senior Vice President of Regulatory Affairs	3.4yrs	Veri yok	Veri yok

2.5yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: SABS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Samuel Reich	CEO & Executive Chairman	4yrs	US$768.40k	0.24% $ 67.0k
Eddie Sullivan	Co-Founder	no data	US$807.76k	5.67% $ 1.6m
Christine Hamilton	Co-Founder & Independent Director	10.8yrs	US$25.00k	5.63% $ 1.6m
Edward Hamilton	Co-Founder & Board Observer	3.1yrs	Veri yok	3.15% $ 890.2k
William Polvino	Independent Director	5.8yrs	US$25.00k	0% $ 0
Jeffrey Spragens	Independent Director	4yrs	US$25.00k	0.43% $ 120.9k
David Link	Independent Vice Chairman	6.8yrs	US$25.00k	0.062% $ 17.5k
Erick Lucera	Independent Director	1.6yrs	US$26.93k	0% $ 0
Jim Robl	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Arturo Casadevall	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Michael Haller	Member of the Clinical Advisory Board & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Stephen Gitelman	Member of Scientific Advisory Board & Member of Clinical Advisory Board	4.8yrs	Veri yok	Veri yok

4.4yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SABS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.4 yıldır).

SAB Biotherapeutics Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Sab Bio Announces Founding of Clinical Advisory Board to Guide the Development of Sab-142 for Type 1 Diabetes

SAB Biotherapeutics, Inc. Appoints Lucy to as Chief Financial Officer, Effective August 12, 2024

SAB Biotherapeutics, Inc., Annual General Meeting, Jun 27, 2024

SAB Biotherapeutics, Inc. Appoints Jay Skyler, Md, to the Board of Directors

SAB Biotherapeutics, Inc. Announces CEO Changes

SAB Biotherapeutics, Inc. Appoints Katie Ellias to the Board of Directors

Recent updates

Third quarter 2024 earnings released: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023)

SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely

Price target decreased by 35% to US$13.00

Consensus revenue estimates increase by 30%

Sab Bio Announces Founding of Clinical Advisory Board to Guide the Development of Sab-142 for Type 1 Diabetes

SAB Biotherapeutics, Inc. Appoints Lucy to as Chief Financial Officer, Effective August 12, 2024

SAB Biotherapeutics, Inc., Annual General Meeting, Jun 27, 2024

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

SAB Biotherapeutics, Inc. announced delayed 10-Q filing

SAB Biotherapeutics, Inc. Appoints Jay Skyler, Md, to the Board of Directors

SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update

Price target increased by 25% to US$25.00

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

SAB Biotherapeutics, Inc. Announces CEO Changes

SAB Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

SAB Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Shareholder dilution

SAB Biotherapeutics Announces Commencement of the Human Phase 1 Clinical Trial with Sab-142

SAB Biotherapeutics, Inc. Appoints Katie Ellias to the Board of Directors

Consensus revenue estimates increase by 61%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 22% to US$2.50

SAB Biotherapeutics, Inc. Appoints Michael G. King Jr. as Chief Financial Officer

SAB Biotherapeutics Appoints Andrew Moin to Board of Directors

Consensus revenue estimates decrease by 51%, EPS upgraded

Consensus revenue estimates decrease by 81%, EPS upgraded

SAB Biotherapeutics, Inc., Annual General Meeting, Jun 29, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

SAB Biotherapeutics, Inc. Announces First Publication of Promising Nonclinical Data for Sab-183 Against Pneumonic Plague in the Journal Antibodies

SAB Biotherapeutics Announces Progress on U.S. FDA's Phased Review of Company's DiversitAb Platform

SAB Biotherapeutics, Inc. Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference

Consensus revenue estimates decrease by 56%, EPS upgraded

Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified

Full year 2022 earnings released: US$0.43 loss per share (vs US$0.63 loss in FY 2021)

Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week

SAB Biotherapeutics, Inc. Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

SAB Biotherapeutics, Inc. announced that it has received $7.884 million in funding

SAB Biotherapeutics Inc. Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes

Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues

Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference

SAB Biotherapeutics Receives a Written Notification from The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Sab Biotherapeutics Unveils New Data At Isirv Options XI Conference Validating SAB-176 Proof of Concept

SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial

SAB Biotherapeutics to Present New Data At Isirv Options Xi Conference on Sab-176 Phase 2A Influenza Trial and Sab-185’S Effectiveness Against Multiple Covid-19 Variants

Consensus revenue estimates fall by 41%

What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03

SAB Biotherapeutics, Inc. Appoints Rear Admiral Scott Giberson to Board of Directors

SAB Biotherapeutics, Inc. Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical Officer

SAB Biotherapeutics, Inc., Annual General Meeting, Jul 06, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$10.35

High number of new directors

High number of new directors

Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term

SAB Biotherapeutics, Inc. Appoints Mark J. Ratain to Its Board of Scientific Advisors

Consensus revenue estimates fall by 25%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$12.63

SAB Biotherapeutics Reports NIH is Discontinuing Phase 3 ACTIV-2 Trial Assessing SAB-185 for Treatment of COVID-19 Due to Declining COVID Hospitalizations